Star Equity Holdings, Inc. Announces 2025 First Quarter Financial Results

2 minutes ago
GlobeNewswire

Q1 2025 revenues increased to $12.9 million vs. $9.1 million in Q1 2024 Alliance Drilling Tools acquisition marks entry into…

Robex Kiniero Project on Track for First Gold in Q4

2 minutes ago

HIGHLIGHTS: Construction at Robex’s Kiniero Gold Project, Guinea, remains on schedule and budget - first gold pour on track for…

Brag House Continues Action to Protect Stockholders Against Potential Illegal Naked Short Selling

2 minutes ago

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Brag House Holdings, Inc. (NASDAQ: TBH) (“Brag House” or the “Company”), the…

NETSOL Technologies Reports Third Quarter Fiscal 2025 Results

2 minutes ago

Total net revenues for Q3’25 increased by 13%, reaching $17.5 million, when compared with Q3’24.Total service revenue increased 24% in…

Blum Holdings Inc. Reports First Quarter 2025 Financial Results

2 minutes ago

Revenue Growth of 26% Year-over-Year, EBITDA Turns Positive Amid Operating Improvements and Streamlined Cost Structure, Net Loss Reduced by Over…

Landsbankinn hf.: Correction – Covered bond exchange offering results – Published: 2025-05-14 14:04:01 CEST

7 minutes ago

Correction: Price, amount and settlement date corrected. In relation to Landsbankinn’s covered bond auction yesterday, was a covered bond exchange…

Rias A/S – Half-Year Report

9 minutes ago

Half-Year Report - RIAS A/S   Attachment Half-Year report for RIAS signed 2025-05-14

Antalpha Announces Pricing of Initial Public Offering

19 minutes ago

SINGAPORE, May 14, 2025 (GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (“Antalpha” or the “Company”) today announced the pricing of…

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

27 minutes ago

Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still…

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

32 minutes ago

ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2…